Company Analysis
Sign in

Organon & Co. (OGN)

NYSE: OGN · Pharmaceutical Preparations · Jersey City, NJ · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.4
◀ Past 6.6● Present 5.9▶ Future 3.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$6.22B-2.9%
Net income$187M-78.4%
Earnings per share$0.72-78.4%
Operating cash flow$700M-25.5%
Cash$574M-15.0%
Debt$8.63B-2.6%
Shareholders’ equity$752M+59.3%
Shares, diluted260.8M+0.6%
Return on equity24.9%
The recordfrom its filings
Filings in 202677
Newest filingNov 10 · 4
Annual reportFeb 24, 2026
Quarterly reportOct 30, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$600,000
Insider buys, 12 months$900,000
Patents granted129
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $6.10BNet income $213MCash from operations $843Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton OGN · research, not advice